BHI Therapeutic Sciences, Inc.

BHI Therapeutic Sciences, Inc. is an international biotechnology company headquartered in Hackensack, New Jersey, in the United States. According to its official website, the company is dedicated to scientific research and education in the field of regenerative medicine, with a particular emphasis on stem cell and regenerative medicine research. Its corporate identity combines research activity with an educational mission, positioning itself within the broader life-sciences and biotechnology sector. The company states that its cellular and exosome products are investigational. They are not approved by the U.S. Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease. The website also carries a disclaimer that nothing on it constitutes medical advice, nor an offer to sell or a solicitation of an offer to buy any security. This language places BHI Therapeutic Sciences in the pre-commercial, research-stage segment of regenerative medicine rather than among companies with marketed therapeutic products. BHI Therapeutic Sciences presents itself as an international biotechnology company, indicating operations or interests beyond the United States. Its public communications highlight participation in the XPRIZE Healthspan competition, where it reached semifinalist status, an achievement the company has publicly reflected on. Such competitions are typically used by early-stage life-science ventures to validate scientific approaches and gain visibility. On the financing side, the company has published a "Testing the Waters" notice indicating that it is considering a potential securities offering in the near future. The notice is intended to gauge potential investor interest and explicitly states that it does not constitute an offer to sell or a solicitation of an offer to buy securities, and that any indication of interest is non-binding. The website also references pre-sale and seed, Series A, and Series B investment stages, along with separate "Invest Now" links for international and U.S. investors, suggesting an ongoing effort to raise capital across multiple rounds. Because the company is at a research and education stage, its public profile is centered on scientific research, investor communications, and competition participation rather than on commercial product sales. Its investigational cellular and exosome products are not FDA-approved, and no approved therapeutic offerings are described in the available evidence. The company remains active as of its public communications.

BHI Therapeutic Sciences, Inc. is a biotechnology company based in Hackensack, New Jersey, United States. Public information about the company is primarily drawn from its official website and a Wikidata entry identifying it as a company in Hackensack. The company presents itself as an international biotechnology company dedicated to scientific research and education in regenerative medicine, with a focus on stem cell research. A central element of the company's public narrative is its participation in the XPRIZE Healthspan competition. According to its website, BHI Therapeutic Sciences reached semifinalist status in that competition and has publicly reflected on the achievement. Competitions of this kind are commonly used by research-stage life-science companies to demonstrate scientific credibility and attract attention from investors and partners. The company has also communicated with potential investors through a "Testing the Waters" notice, stating that it is considering a potential securities offering in the near future. The notice is designed to gauge investor interest and explicitly does not constitute an offer to sell or a solicitation of an offer to buy securities; any expression of interest is non-binding. The website additionally references pre-sale and seed, Series A, and Series B stages, and provides separate "Invest Now" links for international and U.S. investors, indicating an ongoing capital-raising effort. BHI Therapeutic Sciences states that its cellular and exosome products are investigational, are not approved by the U.S. Food and Drug Administration, and are not intended to diagnose, treat, cure, or prevent any disease. The website further disclaims that nothing on it is medical advice or an offer to sell or a solicitation of an offer to buy any security. These statements indicate that the company is at a research and education stage rather than a commercial product stage. No founding date, founder names, ownership structure, or executive leadership are provided in the available evidence. The company's headquarters location is given as Hackensack, New Jersey, and its country of operation is the United States, with an international orientation as described on its website.

• BHI Therapeutic Sciences reaches semifinalist status in the XPRIZE Healthspan competition, an achievement the company later reflects on publicly.

• The company publishes a 'Testing the Waters' notice regarding a potential future securities offering.

An international biotechnology company focused on research and education in stem cell and regenerative medicine, with investigational cellular and exosome products that are not FDA-approved.

• Investigational cellular products

  Cellular products described by the company as investigational, not approved by the FDA, and not intended to diagnose, treat, cure, or prevent any disease.

• Investigational exosome products

  Exosome products described by the company as investigational, not approved by the FDA, and not intended to diagnose, treat, cure, or prevent any disease.

1. 1BLUE HORIZON INTERNATIONAL THERAPEUTIC SCIENCESbhisciences.com
2. 2BHI Therapeutic Sciences, Inc. (United States) - Wikidatawikidata.org